MIKE H. O’NEILL, Director, Analytical Chemistry at Olon Ricerca Bioscience LLC, gave a scientific lecture about Analytical Chemistry in Early-Stage Drug Development at Case Western Reserve University, US.
The presentation gave an overview of the drug development process noting some of the key developmental milestones, introducing also some of the common types of analytical technologies used during development of small molecule active pharmaceutical ingredients. The talk highlighted the importance of Solid-Form screening which aims to improve the physicochemical properties and developability of nascent drug candidates.MIKE H. O’NEILL, Director, Analytical Chemistry at Olon Ricerca Bioscience LLC, gave a scientific lecture about Analytical Chemistry in Early-Stage Drug Development at Case Western Reserve University, US. The presentation gave an overview of the drug development process noting some of the key developmental milestones, introducing also some of the common types of analytical technologies used during development of small molecule active pharmaceutical ingredients. The talk highlighted the importance of Solid-Form screening which aims to improve the physicochemical properties and developability of nascent drug candidates.
Mike’s team is responsible for characterization of active pharmaceutical ingredients, method development, preformulation, stability, quality control, and solid-state form screening. Mike has been named as an inventor on more than 35 patent applications regarding the solid forms of drugs and processes to control drug characteristics.
Milan – Italy, February 20, 2023 – Olon Group and the Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, jointly announce an innovative public-private partnership agreement for a research project on the advanced study of polymorphism and the characterization of the solid state of the molecules of active ingredients.
This strongly internationally oriented, three-year project involves a PhD program dedicated to the development of new knowledge on the polymorphism of active ingredients and to the advancement of methods for characterizing the solid state of their molecules.
The PhD will be undertaken by the researcher Ajay Suresh, Indian Institute of Science Education and Research, Bhopal, India, who will spend the next few years in Italy working on the project and collaborating in synergy with Olon and the Department of Chemistry at the Politecnico di Milano, under the coordination of Professor Pierangelo Metrangolo, ‘Giulio Natta’ Department of Chemistry, Materials and Chemical Engineering and President of the Physical and Biophysical Chemistry Division at the International Union of Pure and Applied Chemistry (IUPAC Div. I).
The strong innovative scope of the project also lies in the model of integration between the Politecnico, the home of academic excellence in terms of knowledge and facilities in the field of crystal chemistry and engineering, and Olon. “The collaboration and exchange of knowledge between two of the leading poles of knowledge and expertise in this area certainly has the potential to produce significant results. The study of polymorphism is one of the most promising areas of study in terms of engineering of molecules, above all because it lays the foundations for the development of much more sustainable and efficient industrial chemical processes,” explained Professor Metrangolo.
“Through this long-term collaboration, we will be able to expand substantially our internal expertise in the analysis and study of the physical state of active ingredients, and at the same time increase our polymorphous screening capabilities. Two key areas of expertise to ensure competitiveness on the global pharmaceutical market,” said Giorgio Bertolini, Head of Research and Development Olon Group.
Mike’s team is responsible for characterization of active pharmaceutical ingredients, method development, preformulation, stability, quality control, and solid-state form screening. Mike has been named as an inventor on more than 35 patent applications regarding the solid forms of drugs and processes to control drug characteristics.
